Reprogenix Bioscience
- Biotech or pharma, therapeutic R&D
Reprogenix, founded in 2014 by renowned stem cell researcher Hongkui Deng and successful serial entrepreneurs Lieming Ding and Casey Lou, developed RGB-5088 and demonstrated for the 1st time achievement of insulin independence in diabetes patients through transplantation of iPSC-derived islets (Wang et al., 2024, Cell 187, 1–13). As reported, the 25-year-old T1D patient received RGB-5088 via injection underneath the anterior abdominal rectus sheath (a new, easily-monitored transplant site), and achieved insulin independence with excellent glycemic control by day 75 after transplantation, and HbA1c of ~5% by 4mo, without signs of malignancy. Insulin independence within 75 days was also achieved in 2 subsequent patients. RGB-5088 has excellent safety & efficacy profiles and is manufactured under GMP condition by differentiating iPSCs that were generated from somatic cells using small molecules alone. Further clinical studies are ongoing, with BLA filing in China planned for 2027.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}